[Asia Economy Reporter Jang Hyowon] Rokit Healthcare is accelerating its entry into the global market by supplying its diabetic foot regeneration treatment platform to Turkey and Mexico.
Global bio-specialized company Rokit Healthcare (CEO Seokhwan Yoo) announced on the 20th that it has signed a supply contract for its diabetic foot regeneration treatment platform worth approximately 7.5 billion KRW over three years with Intra Medical, based in Istanbul, Turkey, and a contract worth about 150 billion KRW over ten years with Fussion Pharma in Mexico.
Rokit Healthcare explained that its technology was recognized through local clinical trials in Turkey. Since last year, the company has been conducting diabetic foot clinical trials at Ankara City Hospital in Turkey, with the head of Yasti Burn Center serving as the principal investigator (P.I), and this year it is also conducting burn clinical trials.
A company representative said, "Our diabetic foot efficacy and technology were recognized locally, leading to this contract. Once the burn clinical trials conclude this year, we expect to expand our business areas."
The company plans to complete regulatory registration with the Mexican health authority (COFEPRIS) within this year. A company representative explained, "Fussion Pharma is a major supplier of diabetes-related medical devices in South America and consists of public insurance experts, so rapid registration is expected. We have already supplied products and services necessary for initial market pioneering, such as 4D bio-printers, to Fussion Pharma, and sales of the diabetic foot regeneration treatment platform are expected to continue from September."
Additionally, since last year, Rokit Healthcare has been accelerating its entry into the South American and other global markets. A company representative said, "In South America, we have been steadily achieving results, starting with a supply contract worth about 100 billion KRW in Colombia at the end of last year. We are building a global distribution network to enter multiple countries."
The company representative added, "Based on EU certification and approval, we are focusing on expanding into Europe as well as South American and Southeast Asian markets that follow the relevant approval guidelines. We expect significant sales growth this year centered on diabetic foot treatment and are striving to achieve profitability in the second quarter."
Meanwhile, in Korea, contract discussions with regional suppliers are underway, starting with the Gyeongsang region. With MFDS approval and other processes currently underway, the company also aims to enter the domestic market this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
